Watch BRNS. Know when insiders buy.
One email the day a filing lands. Free.
BRNS
Barinthus Biotherapeutics plc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$41.8MNET CASH $59.1M52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$11M | −$10.6M | — | -0.26 | −$8.1M | $0 | −$8.1M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$6.1M | −$5.5M | — | -0.14 | −$3.4M | $0 | −$3.4M | Apr 30 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$11.6M | −$11.1M | — | -0.27 | −$4.2M | $0 | −$4.2M | Mar 13 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$15.1M | −$14.6M | — | -0.36 | −$10.7M | $0 | −$10.7M | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$23.3M | −$21.1M | — | -0.52 | −$18.1M | $32K | −$18.1M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$20.6M | −$19.6M | — | -0.49 | −$14.9M | $5K | −$14.9M | Apr 30 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$23.4M | −$20.5M | — | -0.51 | $13.1M | $278K | $12.8M | Mar 13 |
| Q3 2024 · Sep 30 | $15M | — | — | −$9.4M | −$8.1M | — | -0.21 | −$18.2M | $114K | −$18.3M | Nov 7 |
| Q2 2024 · Jun 30 | $0 | — | — | −$18.3M | −$16.9M | — | -0.43 | −$12M | $192K | −$12.2M | Aug 7 |
| Q1 2024 · Mar 31 | $0 | — | — | −$16.9M | −$15.5M | — | -0.40 | −$11.8M | $308K | −$12.1M | May 7 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$20M | −$17.3M | — | -0.45 | −$19.6M | −$153K | −$19.4M | Mar 20 |
| Q3 2023 · Sep 30 | $0 | — | — | −$16.1M | −$14.1M | — | -0.37 | −$11.2M | $36K | −$11.2M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$70.6M | −$66.4M | — | -1.64 | −$48M | $37K | −$48M | — | — |
| FY2024 · to Dec 31 | $15M | — | −$68M | −$61.1M | -408.0% | -1.55 | −$28.9M | $892K | −$29.8M | — | — |
| FY2023 · to Dec 31 | $802K | — | −$83.9M | −$73.3M | -9145.5% | -1.91 | −$50.9M | $5.4M | −$56.3M | — | — |
| FY2022 · to Dec 31 | $44.7M | — | −$4M | $5.3M | 11.9% | 0.14 | −$14.4M | $6.1M | −$20.6M | — | — |
| FY2021 · to Dec 31 | $268K | — | −$45.2M | −$50.9M | -18979.5% | -1.96 | −$32.6M | $1.1M | −$33.7M | — | — |
| FY2020 · to Dec 31 | $4.8M | — | −$20M | −$17.7M | -367.3% | -2.24 | −$11M | $293K | −$11.3M | — | — |
Every number comes from Barinthus Biotherapeutics plc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.